Checking a new treatment approach for liver cancer needing TACE
Treatments studied
Part of Cancer, Digestive system clinical trials.
This early-stage trial studies a new strategy for hepatocellular carcinoma (a type of liver cancer) in people who are planned to receive TACE, a procedure that delivers treatment through the liver’s blood supply. It aims to test whether targeting a specific cell survival process can improve how well the treatment works and is tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have confirmed BCLC B hepatocellular carcinoma (HCC) planned for TACE
- Your tumor is at least 3 cm and shows features on imaging that are considered LI-RADS 5
- Your liver function is good enough to be Child-Pugh A or B7, and you’re fairly well (performance status 0)
- You must be able and willing to follow study visits and procedures for the full study time
- You must not have certain eye, heart rhythm, or medication-ingredient problems that could make participation unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This study tests two different treatment combinations for liver cancer that cannot be removed with surgery. One group gets a treatment called TACE plus a pill combination, and the other gets TACE plus standard targeted immunotherapy. The goal is to see which approach works better.
This trial studies a treatment approach (a combination given through the liver) for people with early liver cancer that can be surgically removed but has a high chance of coming back. It may help reduce the risk of recurrence after treatment.
This trial tests a new medicine (FB-1603) given along with standard TACE procedure for people with liver cancer. It aims to see if the combination is safe and works better than TACE alone.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This trial tests a combination of an immunotherapy drug (QL1706) and a liver-directed procedure (TACE) before and after surgery for people with liver cancer that is larger or more advanced than the usual transplant criteria. The goal is to see if this approach can help shrink the tumor and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.